FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023141374> ?p ?o ?g. }

• W2023141374 endingPage "314" @default.
• W2023141374 startingPage "305" @default.
• W2023141374 abstract "Palliative radiotherapy constitutes nearly 50% of the workload in radiotherapy. Surveys on the patterns of practice in radiotherapy have been published from North America and Europe. Our objective was to determine the current pattern of practice of radiation oncologists in Canada for the palliation of bone metastases.A survey was sent to 300 practicing radiation oncologists in Canada. Five case scenarios were presented. The first three were patients with a single symptomatic site: breast cancer patient with pelvic metastasis, lung cancer male with metastasis to L3 and L1, respectively. The last two were breast and prostate cancer patients with multiple symptomatic bone metastases.A total of 172 questionnaires were returned (57%) for a total of 860 responses. For the three cases with a single painful bone metastasis, over 98% would prescribe radiotherapy. The doses ranged from a single 8 to 30 Gy in ten fractions. Of the 172 respondents, 117 (68%) would use the same dose fractionation for all three cases, suggesting that they had a standard dose fractionation for palliative radiotherapy. The most common dose fractionation was 20 Gy in five fractions used by 84/117 (72%), and 8 Gy in one fraction by 19/117 (16%). In all five case scenarios, 81% would use a short course of radiotherapy (single 8 Gy, 17%; 20 Gy in five fractions, 64%), while 10% would prescribe 30 Gy in ten fractions. For the two cases with diffuse symptomatic bone metastases, half body irradiation (HBI) and radionuclides were recommended more frequently in prostate cancer than in breast cancer (46/172 vs. 4/172, P<0. 0001; and 93/172 vs. 10/172, P<0.0001, respectively). Strontium was the most commonly recommended radionuclide (98/103=95%). Since systemic radionuclides are not readily available in our health care system, 41/98 (42%) of radiation oncologists who would recommend strontium were not familiar with the dose. Bisphosphonates were recommended more frequently in breast cancer than in prostate cancer 13/172 (8%) vs. 1/172 (0.6%), P=0.001.Local field external radiotherapy remains the mainstay of therapy, and the most common fractionation for bone metastases in Canada is 20 Gy in five fractions compared with 30 Gy in ten fractions in the US. Despite randomized trials showing similar results for single compared with fractionated radiotherapy, the majority of us still advocate five fractions. The frequency of employing a single fractionation has not changed since the last national survey in 1992. Nearly 70% use a standard dose fractionation to palliate localized painful metastasis by radiotherapy, independent of the site of involvement or tumor type. The pattern of practice of palliative radiotherapy for bone metastases in Canada is different to that reported previously from the US. The reasons why the results of randomized studies on bone metastases have no impact on the patterns of practice are worth exploring." @default.
• W2023141374 created "2016-06-24" @default.
• W2023141374 creator A5002216968 @default.
• W2023141374 creator A5011082618 @default.
• W2023141374 creator A5030716891 @default.
• W2023141374 creator A5034318633 @default.
• W2023141374 creator A5047114036 @default.
• W2023141374 creator A5059099112 @default.
• W2023141374 creator A5064825265 @default.
• W2023141374 creator A5069654391 @default.
• W2023141374 creator A5073747090 @default.
• W2023141374 date "2000-09-01" @default.
• W2023141374 modified "2023-10-17" @default.
• W2023141374 title "Palliation of bone metastases: a survey of patterns of practice among Canadian radiation oncologists" @default.
• W2023141374 cites W1551816771 @default.
• W2023141374 cites W1768011742 @default.
• W2023141374 cites W1966327604 @default.
• W2023141374 cites W1971021347 @default.
• W2023141374 cites W1973685181 @default.
• W2023141374 cites W1976664800 @default.
• W2023141374 cites W1983514189 @default.
• W2023141374 cites W1986251014 @default.
• W2023141374 cites W1989098069 @default.
• W2023141374 cites W1989291513 @default.
• W2023141374 cites W1990718568 @default.
• W2023141374 cites W1995975133 @default.
• W2023141374 cites W1998887983 @default.
• W2023141374 cites W1999978652 @default.
• W2023141374 cites W2000016107 @default.
• W2023141374 cites W2003786866 @default.
• W2023141374 cites W2006734418 @default.
• W2023141374 cites W2017735814 @default.
• W2023141374 cites W2018054592 @default.
• W2023141374 cites W2023854769 @default.
• W2023141374 cites W2030974023 @default.
• W2023141374 cites W2036541203 @default.
• W2023141374 cites W2037333103 @default.
• W2023141374 cites W2047842438 @default.
• W2023141374 cites W2053808060 @default.
• W2023141374 cites W2065272001 @default.
• W2023141374 cites W2066553392 @default.
• W2023141374 cites W2070408871 @default.
• W2023141374 cites W2076953837 @default.
• W2023141374 cites W2080661941 @default.
• W2023141374 cites W2081945612 @default.
• W2023141374 cites W2083090725 @default.
• W2023141374 cites W2091732713 @default.
• W2023141374 cites W2097514725 @default.
• W2023141374 cites W2098269345 @default.
• W2023141374 cites W2108145085 @default.
• W2023141374 cites W2109963973 @default.
• W2023141374 cites W2126697292 @default.
• W2023141374 cites W2128443828 @default.
• W2023141374 cites W2143745561 @default.
• W2023141374 cites W2155313661 @default.
• W2023141374 cites W2399906468 @default.
• W2023141374 cites W2408935243 @default.
• W2023141374 cites W2637791686 @default.
• W2023141374 doi "https://doi.org/10.1016/s0167-8140(00)00238-3" @default.
• W2023141374 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10974379" @default.
• W2023141374 hasPublicationYear "2000" @default.
• W2023141374 type Work @default.
• W2023141374 sameAs 2023141374 @default.
• W2023141374 citedByCount "103" @default.
• W2023141374 countsByYear W20231413742012 @default.
• W2023141374 countsByYear W20231413742013 @default.
• W2023141374 countsByYear W20231413742014 @default.
• W2023141374 countsByYear W20231413742015 @default.
• W2023141374 countsByYear W20231413742016 @default.
• W2023141374 countsByYear W20231413742017 @default.
• W2023141374 countsByYear W20231413742018 @default.
• W2023141374 countsByYear W20231413742019 @default.
• W2023141374 countsByYear W20231413742020 @default.
• W2023141374 countsByYear W20231413742021 @default.
• W2023141374 countsByYear W20231413742022 @default.
• W2023141374 countsByYear W20231413742023 @default.
• W2023141374 crossrefType "journal-article" @default.
• W2023141374 hasAuthorship W2023141374A5002216968 @default.
• W2023141374 hasAuthorship W2023141374A5011082618 @default.
• W2023141374 hasAuthorship W2023141374A5030716891 @default.
• W2023141374 hasAuthorship W2023141374A5034318633 @default.
• W2023141374 hasAuthorship W2023141374A5047114036 @default.
• W2023141374 hasAuthorship W2023141374A5059099112 @default.
• W2023141374 hasAuthorship W2023141374A5064825265 @default.
• W2023141374 hasAuthorship W2023141374A5069654391 @default.
• W2023141374 hasAuthorship W2023141374A5073747090 @default.
• W2023141374 hasConcept C121608353 @default.
• W2023141374 hasConcept C126322002 @default.
• W2023141374 hasConcept C126838900 @default.
• W2023141374 hasConcept C143998085 @default.
• W2023141374 hasConcept C155806632 @default.
• W2023141374 hasConcept C159110408 @default.
• W2023141374 hasConcept C2776256026 @default.
• W2023141374 hasConcept C2777783956 @default.
• W2023141374 hasConcept C2779013556 @default.
• W2023141374 hasConcept C2780192828 @default.
• W2023141374 hasConcept C2989005 @default.
• W2023141374 hasConcept C2993559085 @default.

• next